Biogen Inc. (NASDAQ:BIIB)

The financial trajectory from 2006 to 2022 is characterized by a significant expansion in operating profitability that outpaced share price growth for much of the period, resulting in a long-term compression of the Price to Operating Profit (P/OP) multiple.

Initial Valuation Compression (2006–2010)

A sharp contraction in the P/OP ratio is observed, falling from a peak of 66.33 in 2006 to 11.26 by 2010. This trend was driven by a rapid escalation in operating profit per share, which increased from 0.69 to 4.80, while the share price experienced more modest gains during the same interval.

Mid-Period Valuation Expansion (2011–2015)

The P/OP ratio entered a period of volatility and growth, reaching a secondary peak of 28.29 in 2014. This shift coincided with a substantial surge in the share price, which climbed from 65.93 in 2011 to a high of 391.12 in 2015. While operating profits continued to rise, the market valuation accelerated at a faster rate during this window.

Operating Profit Peak and Ratio Stabilization (2016–2022)

A general downward trend in the P/OP ratio followed, reaching a historical low of 8.34 in 2020. This period saw operating profit per share reach its maximum value of 40.46 in 2020. Between 2020 and 2022, both the share price and operating profit per share declined, with the P/OP ratio settling at 11.39, indicating a stabilization of the valuation multiple despite falling absolute profitability.